Founded in 2014
About
Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on becoming the leader in the Targeted Alpha Therapy field. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre headquartered at McMaster University. Their Targeted Alpha Therapy has the potential to be used across multiple tumor types including colorectal, bladder, lung cancer and more.
McMaster Founder
John Valliant (Faculty of Science).
Fusion Pharmaceuticals Homepage